Compounding

Unregulated, non-FDA-approved “copycat” GLP-1 drugs are flooding the market, and the patients targeted hardest, including seniors, rural Americans, and communities of color who are priced out of FDA-approved treatment, can least afford a dangerous outcome. HECCD is calling on lawmakers to close the enforcement gaps that let these products spread, and to fix the real problem by expanding coverage of safe, FDA-approved medicines.